The Impact of Intellectual Capital on Bank Profitability during COVID-19: A Comparison with China and Pakistan

This study aims to examine how the relationship between intellectual capital (IC) and bank profitability changed during COVID-19. Based on the data of 34 Chinese banks and 39 Pakistani banks, this study uses ordinary least squares (OLS) to examine this relationship during the COVID-19 era. Profitability is measured by return on assets (ROA) and return on equity (ROE), and IC is measured by the value added intellectual coefficient (VAIC) model. The findings show that, even during the COVID-19 pandemic, IC has managed to sustain its positive influence on bank profitability in China and Pakistan. Among IC components, our study reports that human capital is the only IC resource that continues to enhance ROA and ROE of Chinese and Pakistani banks during the pandemic period. Our study suggests that policymakers should pay more attention to IC resources, which has the potential to improve banks’ profitability even during crisis times.

Combination of natural antivirals and potent immune invigorators: A natural remedy to combat COVID-19.

The flare-up in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in December 2019 in Wuhan, China, and spread expeditiously worldwide has become a health challenge globally. The rapid transmission, absence of anti-SARS-CoV-2 drugs, and inexistence of vaccine are further exacerbating the situation. Several drugs, including chloroquine, remdesivir, and favipiravir, are presently undergoing clinical investigation to further scrutinize their effectiveness and validity in the management of COVID-19. Natural products (NPs) in general, and plants constituents specifically, are unique sources for various effective and novel drugs. Immunostimulants, including vitamins, iron, zinc, chrysin, caffeic acid, and gallic acid, act as potent weapons against COVID-19 by reinvigorating the defensive mechanisms of the immune system. Immunity boosters prevent COVID-19 by stimulating the proliferation of T-cells, B-cells, and neutrophils, neutralizing the free radicals, inhibiting the immunosuppressive agents, and promoting cytokine production. Presently, antiviral therapy includes several lead compounds, such as baicalin, glycyrrhizin, theaflavin, and herbacetin, all of which seem to act against SARS-CoV-2 via particular targets, such as blocking virus entry, attachment to host cell receptor, inhibiting viral replication, and assembly and release.

Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19.

The pandemic coronavirus disease 2019 (COVID-19) is instigated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is mainly transmitted via the inhalation route and characterized by fever, coughing and shortness of breath. COVID-19 affects all age groups with no single cure. The drug discovery, manufacturing, and safety studies require extensive time and sources and, therefore, struggled to match the exponential spread of COVID-19. Yet, various repurposed drugs (antivirals, immune-modulators, nucleotide analogues), and convalescent plasma therapy have been authorized for emergency use against COVID-19 by Food and Drug Administration under certain limits and conditions. The discovery of vaccine is the biggest milestone achieved during the current pandemic era. About nine vaccines were developed for human use with varying claims of efficacy. The rapid emergence of mutations in SARS-CoV-2, suspected adverse drug reactions of current therapies in special population groups and limited availability of drugs in developing countries necessitate the development of more efficacious, safe and cheap drugs/vaccines for treatment and prevention of COVID-19. Keeping in view these limitations, the current review provides an update on the efficacy and safety of the repurposed, and natural drugs to treat COVID-19 as well as the vaccines used for its prophylaxis.

Response of Indonesian universities to the COVID-19 pandemic - between strategy and implementation.

Escalated by mid-January 2020, the Coronavirus Disease 2019 (COVID-19) pandemic is having a profound effect on all aspects of society, including the education activities in higher education. Colleges and universities globally are taking various actions to contain the COVID-19 outbreak. These efforts are mainly to secure the well-being of their students and staff, as well as members of their communities. Due to the increasing number of infections has prompted a number of universities in Indonesia to participate in the fight against the virus outbreak. This article provides an overview of the role played by Indonesian universities dealing with COVID-19 pandemic and how Indonesian universities serving the public good for COVID-19 breakthroughs. The research problem of this study focuses on how the strategies developed by the university in responding to COVID-19 and their implementation to reduce the potential consequences of the pandemic impacts. Subsequently, this paper presented the responses of universities in Indonesia in addressing the COVID-19 pandemic. The forms of responses presented in this paper are academic responses, research and development responses and social community services responses. Furthermore, a conceived information of the issues and challenging of involving of universities in collaborating on solutions to crises of the coronavirus pandemic in Indonesian context were portrayed. In conclusion, this paper summarizes the contribution of Indonesian universities and its impacts in fighting deadly virus disease COVID-19.